Only 5–16% of clinical trials report sex-disaggregated results, revealing a systemic gender bias in medical research that directly harms women’s health outcomes. This persistent gap means treatments are often developed using male-based data, leading to higher rates of adverse drug reactions, misdiagnosis, and poorer long-term health for women. In 2026, policymakers and health organizations are finally pushing for mandatory data disaggregation and targeted investment to address these inequities.
- Only 5–16% of clinical trials report sex-disaggregated results, leaving critical gaps in women’s health evidence (2026 data).
- Women experience 52% more adverse drug events and face 3.5x higher withdrawal risks due to male-based research models.
- Policy shifts in 2026 mandate sex-disaggregated data and view women’s health as a $1 trillion economic opportunity, not niche medicine.
Gender Disparities in Medical Research: Key Statistics and Data Gaps in 2026
The foundation of modern medicine is built on research that systematically under-represents women. In 2026, only 5–16% of clinical trials report results broken down by biological sex, according to analyses from International Women’s Day discussions. This means the vast majority of medical evidence comes from studies on men or mixed groups without separate analysis, creating a “one-size-fits-men” approach to care.
The consequences are not theoretical—they translate into real-world harm, with women spending 25% more of their lives in poor health compared to men. This disparity stems from under-researched conditions like endometriosis, menopause, and autoimmune diseases, which disproportionately affect women but receive scant research attention.
To understand the scale, consider that women make up 78% of autoimmune disease sufferers, yet these conditions remain severely understudied. The menopause and perimenopause affect roughly 16% of the population but capture only 2.5% of the annual research budget. This mismatch between burden and investment is a direct result of historical and ongoing gender bias in research prioritization and design.
5-16% Clinical Trial Reporting and the ‘Small Men’ Fallacy: Male Default in Research
The core issue is the “Small Men” Fallacy—a mindset in research and development that treats female biology as a minor variant of the male default. This assumption leads to several problematic practices: using male animals in preclinical studies because female hormones are seen as complicating variables, dosing drugs based on male metabolism without adjusting for women’s different body composition, and designing trials that exclude women of childbearing age to avoid “liability.” The result is a body of evidence that does not accurately reflect how half the population will respond to treatments.
| Medical Research Area | Typical Sex-Disaggregated Reporting Rate |
|---|---|
| Cardiovascular Disease | ~5% |
| Oncology | ~10% |
| Autoimmune Disorders | ~8% |
| Obstetrics & Gynecology | Up to 16% |
These rates are approximate and reflect aggregated 2026 analyses. Even in women’s health-focused fields like obstetrics and gynecology, reporting rarely exceeds 16%, meaning most studies still fail to provide separate data for men and women. In male-dominated fields like cardiovascular research, rates plummet to around 5%.
This gap persists due to multiple barriers: lack of regulatory requirements, perceived higher costs for sex-specific analysis, and a research culture that has long treated the male body as the universal standard. Without sex-disaggregated data, clinicians cannot make informed decisions about dosage, efficacy, or safety for female patients, perpetuating a cycle of suboptimal care.
Systemic Female Bias: Historical Exclusion and Misrepresentation in Studies
- Historical exclusion from research: Until the 1990s, women were routinely barred from clinical trials, especially early-phase studies, due to fears about potential fetal harm and hormonal variability. This decades-long exclusion created a massive evidence gap that still affects drug development today.
- Over-representation only in ‘female-patient’ dominated areas: A 2024 ABC investigation found that women are over-represented in research perceived as “female-patient dominated” (e.g., breast cancer, obstetrics) but remain significantly underrepresented in studies for conditions that affect both sexes equally, like cardiovascular disease or stroke.
- Lack of sex-specific analysis: Even when women are included in trials, data is often pooled without separate analysis by sex. This means sex-specific outcomes are hidden, and differences in efficacy or side effects go undetected.
- Australian survey findings: The federal government’s Survey Detailed Report (2023) revealed that two thirds of women in Australia experience gender bias when engaging with the healthcare system, citing dismissive attitudes and lack of research into women’s specific health needs.
These patterns are not accidental; they reflect deep-seated structural biases. As one physician noted in a 2024 study, the belief that “I am solely a professional, neutral and genderless” can actually worsen bias by ignoring biological differences that matter for diagnosis and treatment. The result is a medical system that often fails to recognize or address women’s unique health experiences.
How Does Gender Bias in Medical Research Impact Women’s Health Outcomes?
The consequences of this research gap are severe and measurable. Because medical knowledge is built on incomplete data, women face higher risks of adverse drug reactions, misdiagnosis, and delayed treatment. The gender pain gap is particularly stark: women’s symptoms are frequently dismissed as psychological or stress-related, leading to years of suffering before accurate diagnosis.
For conditions like heart disease—the leading cause of death for women—symptoms often present differently than in men, yet research and training remain based on male patterns. This means women are less likely to receive timely interventions like stents or bypass surgery, contributing to higher mortality rates.
The economic and social costs are enormous. With women spending 25% more of their lives in poor health, productivity losses, caregiving burdens, and personal suffering multiply.
Under-researched conditions like endometriosis (affecting 1 in 10 women) have an average diagnosis delay of 7–10 years, during which women endure severe pain and infertility risks. Autoimmune diseases, which are 78% female, often require complex, lifelong management with treatments that were not tested in adequate numbers of women, leading to higher rates of complications.
Women Spend 25% More Time in Poor Health: Autoimmune and Menopause Gaps
The 25% disparity in healthy life years between women and men is not inevitable; it is largely preventable and directly linked to research neglect. Autoimmune diseases—such as lupus, rheumatoid arthritis, and multiple sclerosis—strike women at overwhelmingly higher rates.
Yet research funding and clinical trials for these conditions have historically used male-predominant samples, meaning treatment protocols may not account for female-specific immune responses or hormonal influences. This leads to poorer treatment responses and more side effects for women.
Menopause and perimenopause illustrate the funding gap starkly. Approximately 16% of the population (mostly women aged 45–55) experience these life stages, which can involve debilitating symptoms like hot flashes, sleep disturbances, bone density loss, and cardiovascular changes. Despite this high prevalence, only 2.5% of the annual research budget is dedicated to understanding and treating menopause.
This scarcity of evidence means many women suffer in silence or receive inadequate care from clinicians who lack training in menopausal health. The lifetime impact includes increased risks of osteoporosis, heart disease, and cognitive decline, all of which could be mitigated with better research and earlier intervention.
Adverse Drug Reactions and the Gender Pain Gap: 52% Higher Risk and Misdiagnosis
| Health Outcome | Women vs Men (Since 2000) |
|---|---|
| Adverse drug events reported | 52% more frequent in women |
| Drug withdrawals for safety risks | 3.5 times more likely in women |
| Pain misdiagnosis | Women’s pain often dismissed as stress or psychosomatic |
These disparities stem directly from male-based research models. Drug dosing, metabolism, and side effect profiles are typically established in trials with predominantly male participants.
Women’s smaller average body size, higher body fat percentage, and different liver enzyme activity mean that standard doses can lead to higher blood concentrations and more severe reactions. Since 2000, adverse events have been reported 52% more frequently in women, and medications are 3.5 times more likely to be withdrawn from the market due to safety risks that disproportionately affect women.
The Gender Pain Gap compounds these issues. In cardiovascular disease—often called a “men’s disease”—women’s symptoms like fatigue, nausea, and jaw pain are frequently misattributed to anxiety or indigestion, leading to delayed diagnosis and higher mortality. Similarly, chronic pain conditions such as fibromyalgia and endometriosis are often dismissed as “all in the head,” with patients reporting they must “prove” their symptoms to disbelieving providers.
A 2024 survey by the American Cancer Society found women were more likely to feel they had to convince clinicians of their pain. This dismissive culture, rooted in historical gender stereotypes, means women wait longer for appropriate treatment and suffer unnecessarily.
2026 Policy Responses: Data Mandates, Investment, and Reform
Recognizing the human and economic costs, 2026 has seen a surge in policy initiatives aimed at correcting gender bias in medical research. The central theme is accountability: linking evidence generation to clinical outcomes and regulatory approval.
Regulatory bodies like the FDA, EMA, and Australia’s TGA are facing growing pressure to implement Health Policy Reforms for Gender-Specific Care, making sex-disaggregated data a mandatory condition for drug and device approvals. Without such requirements, the status quo of male-default research persists.
Parallel to regulatory pushes, there is a seismic shift in how women’s health is framed economically. What was once seen as a niche market is now recognized as a $1 trillion opportunity, encompassing everything from FemTech devices to specialized treatments.
However, private investment remains a fraction of what’s needed, creating a “valley of death” between promising research and market-ready solutions. Global initiatives from the McKinsey Health Institute and the World Economic Forum are championing the idea that women’s health is not just a moral imperative but foundational economic infrastructure—improving health for half the population boosts workforce participation, productivity, and GDP.
Mandating Sex-Disaggregated Data and the $1 Trillion FemTech Opportunity
The movement to mandate sex-disaggregated data gained momentum after 2023, with several countries piloting requirements for trial registrations and regulatory submissions. In 2026, the World Economic Forum’s Global Gender Gap Report highlighted that countries with mandatory reporting see 20–30% higher rates of sex-disaggregated data in published trials. The McKinsey Health Institute has launched a global accountability framework that scores pharmaceutical companies on their inclusion of women in trials and analysis of sex-specific outcomes, creating market pressure for change.
Simultaneously, the FemTech sector—technology-enabled solutions for women’s health—is attracting venture capital at an unprecedented rate. Investors are finally seeing what advocates have long argued: women’s health is a massive, underserved market. From fertility tracking apps to menopause management devices, innovation is booming.
Yet, this private investment still represents only a small fraction of total health R&D spending. The challenge is to channel this capital toward under-researched conditions like endometriosis and autoimmune diseases, not just consumer-friendly apps. Framing women’s health as “foundational economic infrastructure” helps shift policy and funding priorities from optional to essential.
Educational Reform and Australian Government Initiatives to End Gender Bias
- Medical school curriculum reform: Leading medical schools worldwide are now incorporating sex and gender-based medicine into core curricula. This trains future doctors to recognize that biological sex affects disease presentation, drug metabolism, and treatment response. Programs like the Australian National University’s “Gender and Health” module are becoming models for systemic change.
- Survey Detailed Report (2023): This landmark Australian government report documented widespread gender bias in healthcare, with two thirds of women reporting dismissive treatment. It called for mandatory sex-disaggregated data collection across the health system and funded pilot programs to test interventions.
-
Monash University report (February 2025): A comprehensive analysis revealed that gender inequities are entrenched even at the highest levels of healthcare policy and research funding.
The report recommended tying grant eligibility to sex-disaggregated reporting and establishing a national women’s health research institute.
- Australian Government report (2024, Blackmores Institute): This independent review found that gender bias in medical research is not just historical but actively perpetuated by current funding and publication practices. It urged the Medical Research Future Fund to allocate dedicated streams for women’s health research.
- Survey finding: Two thirds of women in Australia say they experience gender bias in the health system, according to the survey, underscoring the urgent need for systemic reform.
These initiatives represent a turning point.
The Australian experience, with its government-led surveys and university reports, provides a blueprint for other nations seeking to address their own gender biases in medical research, as outlined in advocacy landscape for women’s health equity.
The most surprising finding is that women spend 25% more of their lives in poor health due to under-researched conditions like endometriosis and autoimmune diseases—a disparity that is largely preventable with equitable research investment. Right now, you can take action by advocating for mandatory sex-disaggregated data in clinical trials.
Support the Australian Government’s initiative or explore women’s health resources that highlight these gaps. Additionally, consider investing in or donating to FemTech startups and research organizations focused on underfunded women’s health conditions, helping to close the evidence gap that has persisted for too long.
Frequently Asked Questions About Gender Bias In Medical Research
What are some consequences of gender bias in healthcare and medical research?
Since 2000, adverse drug events are reported 52% more frequently in women, and drug withdrawals for safety risks are 3.5 times more likely in women. Women's pain is also often dismissed as stress or psychosomatic, leading to misdiagnosis and delayed treatment.
What is the female bias in healthcare?
Gender bias in healthcare refers to the systematic undervaluation of women's symptoms, resulting in misdiagnosis. Evidence includes women's pain being dismissed as stress or psychosomatic, and since 2000, adverse drug events are 52% more frequent in women with drug withdrawals 3.5 times more likely.
